OPA889-1

OPA889-1 is a discovery-stage therapeutic candidate developed by Serilink Biotechnology, a biopharmaceutical company focused on next-generation conjugation technologies. The agent is built using Serilink's proprietary **Orthogonal Proximity-induced Alkylation (OPA)** platform, which is designed to enable site-specific, stable, and homogeneous conjugation of payloads to targeting moieties. While the specific molecular target of OPA889-1 has not been publicly disclosed, it is part of a pipeline targeting solid tumors. The program may represent an antibody-drug conjugate (ADC), peptide-drug conjugate (PDC), or antibody-radionuclide conjugate (ARC), as the OPA technology is applicable across these modalities to improve the therapeutic index and stability of the resulting conjugates.